Tailor made GMP services for viral vector manufacturing and cell engineering.
Novel autologous and allogeneic therapies in pre-clinical and clinical stage for the treatament of cancer
AGC Inc. announces the launch of a voluntary tender offer over all ordinary shares of MolMed S.p.A.
WSI Wall street Italia - MOLMED, LA NUOVA SFIDA DEL BIOTECH ITALIA\O
Q&A with Riccardo Palmisano, MolMed CEO, and Finanzaonline's forum members
Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.
